{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:15Z","timestamp":1786980555052,"version":"build-2736575974"},"reference-count":217,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Scientific and Technological Innovation Leading Talents Project of Zhejiang Provincial \"High-level Talents Special Support Plan\"","award":["2021R52043"],"award-info":[{"award-number":["2021R52043"]}]},{"name":"Scientific and Technological Innovation Leading Talents Project of Zhejiang Provincial \"High-level Talents Special Support Plan\"","award":["2021R52043"],"award-info":[{"award-number":["2021R52043"]}]},{"name":"Scientific and Technological Innovation Leading Talents Project of Zhejiang Provincial \"High-level Talents Special Support Plan\"","award":["2021R52043"],"award-info":[{"award-number":["2021R52043"]}]},{"name":"Scientific and Technological Innovation Leading Talents Project of Zhejiang Provincial \"High-level Talents Special Support Plan\"","award":["2021R52043"],"award-info":[{"award-number":["2021R52043"]}]},{"name":"Scientific and Technological Innovation Leading Talents Project of Zhejiang Provincial \"High-level Talents Special Support Plan\"","award":["2021R52043"],"award-info":[{"award-number":["2021R52043"]}]},{"name":"Key Project of Zhejiang Provincial Natural Science Foundation of China","award":["LZ22C010003"],"award-info":[{"award-number":["LZ22C010003"]}]},{"name":"Key Project of Zhejiang Provincial Natural Science Foundation of China","award":["LZ22C010003"],"award-info":[{"award-number":["LZ22C010003"]}]},{"name":"Key Project of Zhejiang Provincial Natural Science Foundation of China","award":["LZ22C010003"],"award-info":[{"award-number":["LZ22C010003"]}]},{"name":"Key Project of Zhejiang Provincial Natural Science Foundation of China","award":["LZ22C010003"],"award-info":[{"award-number":["LZ22C010003"]}]},{"name":"Key Project of Zhejiang Provincial Natural Science Foundation of China","award":["LZ22C010003"],"award-info":[{"award-number":["LZ22C010003"]}]},{"name":"Zhejiang Science and Technology Major Program on Agricultural New Variety Breeding","award":["2021C02068-4"],"award-info":[{"award-number":["2021C02068-4"]}]},{"name":"Zhejiang Science and Technology Major Program on Agricultural New Variety Breeding","award":["2021C02068-4"],"award-info":[{"award-number":["2021C02068-4"]}]},{"name":"Zhejiang Science and Technology Major Program on Agricultural New Variety Breeding","award":["2021C02068-4"],"award-info":[{"award-number":["2021C02068-4"]}]},{"name":"Zhejiang Science and Technology Major Program on Agricultural New Variety Breeding","award":["2021C02068-4"],"award-info":[{"award-number":["2021C02068-4"]}]},{"name":"Zhejiang Science and Technology Major Program on Agricultural New Variety Breeding","award":["2021C02068-4"],"award-info":[{"award-number":["2021C02068-4"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32202656, 32402753"],"award-info":[{"award-number":["32202656, 32402753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32202656, 32402753"],"award-info":[{"award-number":["32202656, 32402753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32202656, 32402753"],"award-info":[{"award-number":["32202656, 32402753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32202656, 32402753"],"award-info":[{"award-number":["32202656, 32402753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32202656, 32402753"],"award-info":[{"award-number":["32202656, 32402753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LQ23C170003, LQ23C180003 & LQ24C170001"],"award-info":[{"award-number":["LQ23C170003, LQ23C180003 & LQ24C170001"]}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LQ23C170003, LQ23C180003 & LQ24C170001"],"award-info":[{"award-number":["LQ23C170003, LQ23C180003 & LQ24C170001"]}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LQ23C170003, LQ23C180003 & LQ24C170001"],"award-info":[{"award-number":["LQ23C170003, LQ23C180003 & LQ24C170001"]}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LQ23C170003, LQ23C180003 & LQ24C170001"],"award-info":[{"award-number":["LQ23C170003, LQ23C180003 & LQ24C170001"]}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LQ23C170003, LQ23C180003 & LQ24C170001"],"award-info":[{"award-number":["LQ23C170003, LQ23C180003 & LQ24C170001"]}]},{"name":"Zhejiang A&F University Talent Initiative Project","award":["Nos: 2019FR022, 2021FR004, 2022LFR037 & 2024LFR066"],"award-info":[{"award-number":["Nos: 2019FR022, 2021FR004, 2022LFR037 & 2024LFR066"]}]},{"name":"Zhejiang A&F University Talent Initiative Project","award":["Nos: 2019FR022, 2021FR004, 2022LFR037 & 2024LFR066"],"award-info":[{"award-number":["Nos: 2019FR022, 2021FR004, 2022LFR037 & 2024LFR066"]}]},{"name":"Zhejiang A&F University Talent Initiative Project","award":["Nos: 2019FR022, 2021FR004, 2022LFR037 & 2024LFR066"],"award-info":[{"award-number":["Nos: 2019FR022, 2021FR004, 2022LFR037 & 2024LFR066"]}]},{"name":"Zhejiang A&F University Talent Initiative Project","award":["Nos: 2019FR022, 2021FR004, 2022LFR037 & 2024LFR066"],"award-info":[{"award-number":["Nos: 2019FR022, 2021FR004, 2022LFR037 & 2024LFR066"]}]},{"name":"Zhejiang A&F University Talent Initiative Project","award":["Nos: 2019FR022, 2021FR004, 2022LFR037 & 2024LFR066"],"award-info":[{"award-number":["Nos: 2019FR022, 2021FR004, 2022LFR037 & 2024LFR066"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Funct Integr Genomics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10142-025-01756-1","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T02:53:58Z","timestamp":1763434438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cellular and molecular targets in \u03b2-Thalassemia: advances in iron Regulation, Erythropoiesis, and Gene-Based therapies"],"prefix":"10.1007","volume":"25","author":[{"given":"Xueting","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianlian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"1756_CR1","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1001\/jama.1898.02440760054013","volume":"24","author":"TB Cooley","year":"1900","unstructured":"Cooley TB, Lee P (1900) Transactions of the American pediatric society. Edinb Med J 24:1426. https:\/\/doi.org\/10.1001\/jama.1898.02440760054013","journal-title":"Edinb Med J"},{"issue":"3","key":"1756_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/archpedi.1927.04130210022002","volume":"34","author":"TB Cooley","year":"1927","unstructured":"Cooley TB, Witwer ER, Lee P (1927) Anemia in children: with splenomegaly and peculiar changes in the bones report of cases. Am J Dis Child 34(3):347\u2013363. https:\/\/doi.org\/10.1001\/archpedi.1927.04130210022002","journal-title":"Am J Dis Child"},{"issue":"3","key":"1756_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0022-3476(36)80021-3","volume":"9","author":"GH Whipple","year":"1936","unstructured":"Whipple GH, Bradford WL (1936) Mediterranean disease-thalassemia(erythroblastic anemia of cooley). J Pediatr 9(3):279\u2013311. https:\/\/doi.org\/10.1016\/S0022-3476(36)80021-3","journal-title":"J Pediatr"},{"issue":"13","key":"1756_CR4","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1182\/blood-2010-08-300335","volume":"118","author":"EA Rachmilewitz","year":"2011","unstructured":"Rachmilewitz EA, Giardina PJ (2011) How I treat thalassemia. Blood 118(13):3479\u20133488. https:\/\/doi.org\/10.1182\/blood-2010-08-300335","journal-title":"Blood"},{"issue":"11","key":"1756_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/ajh.23565","volume":"88","author":"O Oliveros","year":"2013","unstructured":"Oliveros O, Trachtenberg F, Haines D et al (2013) Pain over time and its effects on life in thalassemia. Am J Hematol 88(11):939\u2013943. https:\/\/doi.org\/10.1002\/ajh.23565","journal-title":"Am J Hematol"},{"issue":"1","key":"1756_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1750-1172-5-11","volume":"5","author":"R Galanello","year":"2010","unstructured":"Galanello R, Origa R, Galanello R, Origa R (2010) Beta-thalassemia. Orphanet J Rare Dis 5(1):11. https:\/\/doi.org\/10.1186\/1750-1172-5-11","journal-title":"Orphanet J Rare Dis"},{"key":"1756_CR7","unstructured":"Vaughan JM, Turnbull HM (1936) The anaemias, (2d edn). Oxford Medical Publications. Oxford University Press, H. Milford, xiv, 309, p 1"},{"issue":"6","key":"1756_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3324\/haematol.2012.066845","volume":"98","author":"KM Musallam","year":"2013","unstructured":"Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA (2013) Non-transfusion-dependent thalassemias. Haematologica 98(6):833\u2013844. https:\/\/doi.org\/10.3324\/haematol.2012.066845","journal-title":"Haematologica"},{"key":"1756_CR9","doi-asserted-by":"publisher","first-page":"e2017018","DOI":"10.4084\/MJHID.2017.018","volume":"9","author":"V De Sanctis","year":"2017","unstructured":"De Sanctis V, Kattamis C, Canatan D et al (2017) \u03b2-Thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterr J Hematol I 9:e2017018. https:\/\/doi.org\/10.4084\/MJHID.2017.018","journal-title":"Mediterr J Hematol I"},{"issue":"4","key":"1756_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1309\/AJCPORRCP16WILSB","volume":"132","author":"G Gibbs","year":"2009","unstructured":"Gibbs G (2009) Separating thalassemia trait and iron deficiency by even simpler inspection. Am J Clin Pathol 132(4):643\u2013644. https:\/\/doi.org\/10.1309\/AJCPORRCP16WILSB","journal-title":"Am J Clin Pathol"},{"key":"1756_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.thromres.2016.08.024","volume":"146","author":"N Sirachainan","year":"2016","unstructured":"Sirachainan N, Chuansumrit A, Kadegasem P, Sasanakul W, Wongwerawattanakoon P, Mahaklan L (2016) Normal hemostatic parameters in children and young adults with \u03b1-thalassemia diseases. Thromb Res 146:35\u201342. https:\/\/doi.org\/10.1016\/j.thromres.2016.08.024","journal-title":"Thromb Res"},{"key":"1756_CR12","doi-asserted-by":"crossref","unstructured":"Haemoglobin (2006) and The genetics of haemoglobin synthesis. Haemoglobinopathy Diagnosis, 1\u201325","DOI":"10.1002\/9780470988787.ch1"},{"issue":"1","key":"1756_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/08998280.2007.11928230","volume":"20","author":"AJ Marengo-Rowe","year":"2007","unstructured":"Marengo-Rowe AJ (2007) The thalassemias and related disorders. Baylor Univ Med Cent Proc 20(1):27\u201331. https:\/\/doi.org\/10.1080\/08998280.2007.11928230","journal-title":"Baylor Univ Med Cent Proc"},{"issue":"6","key":"1756_CR14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S2213-2600(13)70078-X","volume":"1","author":"A Anthi","year":"2013","unstructured":"Anthi A, Orfanos SE, Armaganidis A (2013) Pulmonary hypertension in beta thalassaemia. Lancet Respir Med Aug 1(6):488\u2013496. https:\/\/doi.org\/10.1016\/S2213-2600(13)70078-X","journal-title":"Lancet Respir Med Aug"},{"key":"1756_CR15","doi-asserted-by":"publisher","unstructured":"Mehta P (2012)\u00a0Disorders of hemoglobin: genetics, pathophysiology, and clinical management. JAMA 307(12).\u00a0https:\/\/doi.org\/10.1001\/jama.2012.348","DOI":"10.1001\/jama.2012.348"},{"key":"1756_CR16","doi-asserted-by":"crossref","unstructured":"Saunthararajah Y, Atweh GF (2009) Induction of fetal hemoglobin in the treatment of sickle cell disease and \u03b2 thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ (eds) Disorders of hemoglobin: genetics, pathophysiology, and clinical management, (2 edn). Cambridge University Press, pp 745\u2013754","DOI":"10.1017\/CBO9780511596582.041"},{"issue":"9813","key":"1756_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0140-6736(11)60283-3","volume":"28","author":"DR Higgs","year":"2012","unstructured":"Higgs DR, Engel JD, Stamatoyannopoulos G (2012) Thalassaemia. Lancet 28(9813):373\u2013383. https:\/\/doi.org\/10.1016\/S0140-6736(11)60283-3","journal-title":"Lancet"},{"issue":"4","key":"1756_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3324\/haematol.2014.114827","volume":"100","author":"S Rivella","year":"2015","unstructured":"Rivella S (2015) \u03b2-thalassemias: paradigmatic diseases for scientific discoveries and d evelopment of innovative therapies. Haematologica 100(4):418\u2013430. https:\/\/doi.org\/10.3324\/haematol.2014.114827","journal-title":"Haematologica"},{"key":"1756_CR19","doi-asserted-by":"crossref","unstructured":"Weatherall DJ, Clegg JB (2001) The \u03b2 Thalassaemias. The thalassaemia syndromes 285\u2013356","DOI":"10.1002\/9780470696705.ch7"},{"key":"1756_CR20","unstructured":"Weatherall DJ, Clegg JB (2008) The thalassaemia syndromes, (4th edn)"},{"issue":"22","key":"1756_CR21","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1182\/blood-2010-01-251348","volume":"115","author":"DJ Weatherall","year":"2010","unstructured":"Weatherall DJ (2010) The inherited diseases of hemoglobin are an emerging global health burden. Blood 115(22):4331\u20136. https:\/\/doi.org\/10.1182\/blood-2010-01-251348","journal-title":"Blood"},{"issue":"8","key":"1756_CR22","first-page":"704","volume":"79","author":"DJ Weatherall","year":"2001","unstructured":"Weatherall DJ, Clegg JB (2001) Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 79(8):704\u2013712","journal-title":"Bull World Health Organ"},{"issue":"7","key":"1756_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2174\/156652408786241375","volume":"8","author":"DJ Weatherall","year":"2008","unstructured":"Weatherall DJ (2008) Hemoglobinopathies worldwide: present and future. Curr Mol Med 8(7):592\u2013599. https:\/\/doi.org\/10.2174\/156652408786241375","journal-title":"Curr Mol Med"},{"issue":"11","key":"1756_CR24","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1056\/NEJMra050436","volume":"15","author":"D Rund","year":"2005","unstructured":"Rund D, Rachmilewitz E (2005) Beta-thalassemia. N Engl J Med Sep 15(11):1135\u20131146. https:\/\/doi.org\/10.1056\/NEJMra050436","journal-title":"N Engl J Med Sep"},{"issue":"6","key":"1756_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/gim.2016.173","volume":"19","author":"R Origa","year":"2017","unstructured":"Origa R (2017) beta-Thalassemia. Genet Med Jun 19(6):609\u2013619. https:\/\/doi.org\/10.1038\/gim.2016.173","journal-title":"Genet Med Jun"},{"issue":"7","key":"1756_CR26","doi-asserted-by":"publisher","first-page":"e103020","DOI":"10.1371\/journal.pone.0103020","volume":"9","author":"P Kountouris","year":"2014","unstructured":"Kountouris P, Lederer CW, Fanis P, Feleki X, Old J, Kleanthous M (2014) IthaGenes: an interactive database for haemoglobin variations and epidemiology. PLoS ONE 9(7):e103020. https:\/\/doi.org\/10.1371\/journal.pone.0103020","journal-title":"PLoS ONE"},{"issue":"2","key":"1756_CR27","doi-asserted-by":"publisher","first-page":"a011775","DOI":"10.1101\/cshperspect.a011775","volume":"1","author":"A Cao","year":"2013","unstructured":"Cao A, Kan YW (2013) The prevention of thalassemia. Cold Spring Harb Perspect Med 1(2):a011775. https:\/\/doi.org\/10.1101\/cshperspect.a011775","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1756_CR28","doi-asserted-by":"crossref","unstructured":"Weatherall DJ, Clegg JB\u00a0(2001) Distribution and population genetics of the thalassaemias. Thalassaemia Syndr: 237\u2013284","DOI":"10.1002\/9780470696705.ch6"},{"key":"1756_CR29","doi-asserted-by":"publisher","unstructured":"Thein SL (2013) The molecular basis of \u03b2-Thalassemia. Csh Perspect Med 3(5). https:\/\/doi.org\/10.1101\/cshperspect.a011700","DOI":"10.1101\/cshperspect.a011700"},{"issue":"9","key":"1756_CR30","doi-asserted-by":"publisher","first-page":"a011692","DOI":"10.1101\/cshperspect.a011692","volume":"2","author":"TN Williams","year":"2012","unstructured":"Williams TN, Weatherall DJ (2012) World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb Perspect Med 2(9):a011692. https:\/\/doi.org\/10.1101\/cshperspect.a011692","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"1756_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/GIM.0b013e3181cd68ed","volume":"12","author":"A Cao","year":"2010","unstructured":"Cao A, Galanello R (2010) Beta-thalassemia. Genet Med 12(2):61\u201376. https:\/\/doi.org\/10.1097\/GIM.0b013e3181cd68ed","journal-title":"Genet Med"},{"key":"1756_CR32","doi-asserted-by":"publisher","first-page":"100588","DOI":"10.1016\/j.blre.2019.100588","volume":"37","author":"FT Shah","year":"2019","unstructured":"Shah FT, Sayani F, Trompeter S, Drasar E, Piga A (2019) Challenges of blood transfusions in beta-thalassemia. Blood Rev Sep 37:100588. https:\/\/doi.org\/10.1016\/j.blre.2019.100588","journal-title":"Blood Rev Sep"},{"key":"1756_CR33","doi-asserted-by":"publisher","first-page":"102619","DOI":"10.1016\/j.eclinm.2024.102619","volume":"72","author":"Y Tuo","year":"2024","unstructured":"Tuo Y, Li Y, Li Y et al (2024) Global, regional, and national burden of thalassemia, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. EClinicalMedicine 72:102619. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102619","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1756_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12185-018-2411-9","volume":"108","author":"C Asadov","year":"2018","unstructured":"Asadov C, Alimirzoeva Z, Mammadova T, Aliyeva G, Gafarova S, Mammadov J (2018) beta-Thalassemia intermedia: a comprehensive overview and novel approaches. Int J Hematol Jul 108(1):5\u201321. https:\/\/doi.org\/10.1007\/s12185-018-2411-9","journal-title":"Int J Hematol Jul"},{"issue":"8","key":"1756_CR35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMra2021838","volume":"25","author":"AT Taher","year":"2021","unstructured":"Taher AT, Musallam KM, Cappellini MD (2021) beta-Thalassemias. N Engl J Med Feb 25(8):727\u2013743. https:\/\/doi.org\/10.1056\/NEJMra2021838","journal-title":"N Engl J Med Feb"},{"issue":"11","key":"1756_CR36","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3324\/haematol.2011.055962","volume":"96","author":"F Danjou","year":"2011","unstructured":"Danjou F, Anni F, Galanello R (2011) Beta-thalassemia: from genotype to phenotype. Haematologica 96(11):1573\u20131575. https:\/\/doi.org\/10.3324\/haematol.2011.055962","journal-title":"Haematologica"},{"key":"1756_CR37","doi-asserted-by":"crossref","unstructured":"Zakaria NA, Islam MA, Abdullah WZ et al (2021) Epigenetic insights and potential modifiers as therapeutic targets in \u5c3e\u9225\u63dfhalassemia","DOI":"10.3390\/biom11050755"},{"issue":"5","key":"1756_CR38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1365-2141.2010.08486.x","volume":"152","author":"AT Taher","year":"2011","unstructured":"Taher AT, Musallam KM, Cappellini MD, Weatherall DJ (2011) Optimal management of beta thalassaemia intermedia. Br J Haematol Mar 152(5):512\u2013523. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08486.x","journal-title":"Br J Haematol Mar"},{"issue":"2","key":"1756_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1086\/432519","volume":"77","author":"DP Kwiatkowski","year":"2005","unstructured":"Kwiatkowski DP (2005) How malaria has affected the human genome and what human genetics can teach Us about malaria. Am J Hum Genet 77(2):171\u2013192. https:\/\/doi.org\/10.1086\/432519","journal-title":"Am J Hum Genet"},{"issue":"7045","key":"1756_CR40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/nature03631","volume":"435","author":"RM Fairhurst","year":"2005","unstructured":"Fairhurst RM, Baruch DI, Brittain NJ et al (2005) Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. Nature. https:\/\/doi.org\/10.1038\/nature03631","journal-title":"Nature"},{"issue":"3","key":"1756_CR41","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1073\/pnas.0711401105","volume":"22","author":"R Cholera","year":"2008","unstructured":"Cholera R, Brittain NJ, Gillrie MR et al (2008) Impaired cytoadherence of plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. Proc Natl Acad Sci U S A 22(3):991\u2013996. https:\/\/doi.org\/10.1073\/pnas.0711401105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6060","key":"1756_CR42","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1126\/science.1213775","volume":"2","author":"M Cyrklaff","year":"2011","unstructured":"Cyrklaff M, Sanchez CP, Kilian N et al (2011) Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum-infected erythrocytes. Science. https:\/\/doi.org\/10.1126\/science.1213775","journal-title":"Science"},{"issue":"5","key":"1756_CR43","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1371\/journal.pmed.0020128","volume":"2","author":"TN Williams","year":"2005","unstructured":"Williams TN, Mwangi TW, Roberts DJ et al (2005) An immune basis for malaria protection by the sickle cell trait. PLoS Med 2(5):e128. https:\/\/doi.org\/10.1371\/journal.pmed.0020128","journal-title":"PLoS Med"},{"issue":"16","key":"1756_CR44","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1182\/blood-2011-08-371062","volume":"19","author":"L Gong","year":"2012","unstructured":"Gong L, Maiteki-Sebuguzi C, Rosenthal PJ et al (2012) Evidence for both innate and acquired mechanisms of protection from in children with sickle cell trait. Blood Apr 19(16):3808\u20133814. https:\/\/doi.org\/10.1182\/blood-2011-08-371062","journal-title":"Blood Apr"},{"key":"1756_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-280","author":"J Veenemans","year":"2011","unstructured":"Veenemans J, Jansen EJS, Baidjoe AY et al (2011) Effect of \u03b1 (+)-thalassaemia on episodes of fever due to malaria and othe r causes: a community-based cohort study in Tanzania. Malar J. https:\/\/doi.org\/10.1186\/1475-2875-10-280","journal-title":"Malar J"},{"issue":"10","key":"1756_CR46","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1086\/429832","volume":"191","author":"G Cabrera","year":"2005","unstructured":"Cabrera G, Cot M, Migot-Nabias F, Kremsner Peter G, Deloron P, Luty Adrian JF (2005) The sickle cell trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium falciparum variant surface antigens. J Infect Dis 191(10):1631\u20131638. https:\/\/doi.org\/10.1086\/429832","journal-title":"J Infect Dis"},{"issue":"11","key":"1756_CR47","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/infdis\/jir638","volume":"204","author":"X Tan","year":"2011","unstructured":"Tan X, Traore B, Kayentao K et al (2011) Hemoglobin S and C heterozygosity enhances neither the magnitude nor breadth of antibody responses to a diverse array of Plasmodium falciparum antigens. J Infect Dis 204(11):1750\u20131761","journal-title":"J Infect Dis"},{"issue":"10","key":"1756_CR48","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1182\/blood-2003-11-3820","volume":"104","author":"K Ayi","year":"2004","unstructured":"Ayi K, Turrini F, Piga A, Arese P (2004) Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. Blood 104(10):3364\u20133371. https:\/\/doi.org\/10.1182\/blood-2003-11-3820","journal-title":"Blood"},{"key":"1756_CR49","doi-asserted-by":"publisher","unstructured":"Steinberg MH, Forget BG, Higgs DR, Weatherall DJ (2009) Disorders of hemoglobin (Genetics, pathophysiology, and clinical management) || Sickle cell pain: biology, etiology, and treatment, 497\u2013524 https:\/\/doi.org\/10.1017\/CBO9780511596582(20)","DOI":"10.1017\/CBO9780511596582(20)"},{"issue":"22","key":"1756_CR50","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1182\/blood-2011-12-397729","volume":"31","author":"E Khandros","year":"2012","unstructured":"Khandros E, Thom CS, D\u2019Souza J, Weiss MJ (2012) Integrated protein quality-control pathways regulate free alpha-globin in murine beta-thalassemia. Blood May 31(22):5265\u20135275. https:\/\/doi.org\/10.1182\/blood-2011-12-397729","journal-title":"Blood May"},{"issue":"7095","key":"1756_CR51","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1136\/bmj.314.7095.1675","volume":"314","author":"DJ Weatherall","year":"1997","unstructured":"Weatherall DJ (1997) The thalassaemias. BMJ 314(7095):1675\u20138. https:\/\/doi.org\/10.1136\/bmj.314.7095.1675","journal-title":"BMJ"},{"issue":"12","key":"1756_CR52","doi-asserted-by":"publisher","first-page":"a011726-a011726","DOI":"10.1101\/cshperspect.a011726","volume":"2","author":"AW Nienhuis","year":"2012","unstructured":"Nienhuis AW, Nathan DG (2012) Pathophysiology and clinical manifestations of the -Thalassemias. Cold Spring Harb Perspect Med 2(12):a011726-a011726. https:\/\/doi.org\/10.1101\/cshperspect.a011726","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"1756_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/abio.370040210","volume":"4","author":"M Prause","year":"1984","unstructured":"Prause M, Schulz HJ, Wagler D (1984) Rechnergest\u00fctzte F\u00fchrung von Fermentationsprozessen, Teil 2. Acta Biotechnol 4(2):143\u2013151. https:\/\/doi.org\/10.1002\/abio.370040210","journal-title":"Acta Biotechnol"},{"key":"1756_CR54","unstructured":"Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A (2008) Guidelines for the clinical management of thalassaemia. Thalassaemia International Federation. 2(nd) Revised ed"},{"issue":"9","key":"1756_CR55","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1182\/blood-2003-11-3957","volume":"103","author":"V Viprakasit","year":"2004","unstructured":"Viprakasit V, Tanphaichitr VS, Chinchang W, Sangkla P, Higgs DR (2004) Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with beta thalassemia. Blood 103(9):3296\u20133299","journal-title":"Blood"},{"key":"1756_CR56","doi-asserted-by":"crossref","unstructured":"Thein SL (2008) Genetic modifiers of the beta-haemoglobinopathies. Br J Haematol 141(3)","DOI":"10.1111\/j.1365-2141.2008.07084.x"},{"issue":"9","key":"1756_CR57","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/ng.630","volume":"42","author":"J Borg","year":"2010","unstructured":"Borg J, Papadopoulos P, Georgitsi M et al (2010) Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 42(9):801\u2013805. https:\/\/doi.org\/10.1038\/ng.630","journal-title":"Nat Genet"},{"issue":"6270","key":"1756_CR58","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.aad3312","volume":"351","author":"T Masuda","year":"2016","unstructured":"Masuda T, Wang X, Maeda M et al (2016) Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science. https:\/\/doi.org\/10.1126\/science.aad3312","journal-title":"Science"},{"issue":"5909","key":"1756_CR59","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1126\/science.1165409","volume":"322","author":"VG Sankaran","year":"2008","unstructured":"Sankaran VG, Menne TF, Xu J et al (2008) Human fetal hemoglobin expression is regulated by the developmental st age-specific repressor BCL11A. Science 322(5909):1839\u20131842. https:\/\/doi.org\/10.1126\/science.1165409","journal-title":"Science"},{"issue":"3","key":"1756_CR60","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1086\/381402","volume":"74","author":"D Weatherall","year":"2003","unstructured":"Weatherall D (2003) William Allan Award address The Thalassemias: the role of molecular genetics in an evolving global health problem. Am J Hum Genet 74(3):385\u2013392. https:\/\/doi.org\/10.1086\/381402","journal-title":"Am J Hum Genet"},{"issue":"4","key":"1756_CR61","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1046\/j.1365-2141.2001.03200.x","volume":"115","author":"R Galanello","year":"2001","unstructured":"Galanello R, Piras S, Barella S et al (2001) Cholelithiasis and gilbert\u2019s syndrome in homozygous beta-thalassaemia. Br J Haematol Dec 115(4):926\u2013928. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03200.x","journal-title":"Br J Haematol Dec"},{"key":"1756_CR62","unstructured":"Lynch EC (1990) Peripheral Blood Smear. PubMed"},{"issue":"1","key":"1756_CR63","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1749-6632.2010.05550.x","volume":"2010","author":"C Borgna-Pignatti","year":"2010","unstructured":"Borgna-Pignatti C, Marsella M, Zanforlin N (2010) The natural history of thalassemia intermedia. Ann N Y Acad Sci 2010(1):214\u2013220. https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05550.x","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"1756_CR64","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bcmd.2006.04.005","volume":"37","author":"A Taher","year":"2006","unstructured":"Taher A, Isma\u2019eel H, Cappellini MD (2006) Thalassemia intermedia: revisited. Blood Cells Mol Dis Jul-Aug 37(1):12\u201320. https:\/\/doi.org\/10.1016\/j.bcmd.2006.04.005","journal-title":"Blood Cells Mol Dis Jul-Aug"},{"issue":"1","key":"1756_CR65","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood.v99.1.36","volume":"1","author":"A Eldor","year":"2002","unstructured":"Eldor A, Rachmilewitz EA (2002) The hypercoagulable state in thalassemia. Blood 1(1):36\u201343. https:\/\/doi.org\/10.1182\/blood.v99.1.36","journal-title":"Blood"},{"key":"1756_CR66","doi-asserted-by":"publisher","first-page":"100594","DOI":"10.1016\/j.blre.2019.100594","volume":"38","author":"VM Pinto","year":"2019","unstructured":"Pinto VM, Poggi M, Russo R, Giusti A, Forni GL (2019) Management of the aging beta-thalassemia transfusion-dependent population - the Italian experience. Blood Rev 38:100594. https:\/\/doi.org\/10.1016\/j.blre.2019.100594","journal-title":"Blood Rev"},{"issue":"17","key":"1756_CR67","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1182\/blood-2018-06-818187","volume":"25","author":"AT Taher","year":"2018","unstructured":"Taher AT, Cappellini MD (2018) How i manage medical complications of \u03b2-thalassemia in adults. Blood 25(17):1781\u20131791. https:\/\/doi.org\/10.1182\/blood-2018-06-818187","journal-title":"Blood"},{"issue":"5","key":"1756_CR68","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.thromres.2012.07.013","volume":"130","author":"KM Musallam","year":"2012","unstructured":"Musallam KM, Taher AT, Karimi M, Rachmilewitz EA (2012) Cerebral infarction in beta-thalassemia intermedia: breaking the silence. Thromb Res Nov 130(5):695\u2013702. https:\/\/doi.org\/10.1016\/j.thromres.2012.07.013","journal-title":"Thromb Res Nov"},{"issue":"10","key":"1756_CR69","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1182\/blood-2009-09-243154","volume":"115","author":"AT Taher","year":"2010","unstructured":"Taher AT, Musallam KM, Karimi M et al (2010) Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. https:\/\/doi.org\/10.1182\/blood-2009-09-243154","journal-title":"Blood"},{"issue":"6","key":"1756_CR70","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ejim.2011.05.013","volume":"22","author":"M Karimi","year":"2011","unstructured":"Karimi M, Musallam KM, Cappellini MD et al (2011) Risk factors for pulmonary hypertension in patients with \u03b2 thalassemia intermedia. Eur J Intern Med 22(6):607\u2013610. https:\/\/doi.org\/10.1016\/j.ejim.2011.05.013","journal-title":"Eur J Intern Med"},{"issue":"12","key":"1756_CR71","doi-asserted-by":"publisher","first-page":"a011726","DOI":"10.1101\/cshperspect.a011726","volume":"1","author":"AW Nienhuis","year":"2012","unstructured":"Nienhuis AW, Nathan DG (2012) Pathophysiology and clinical manifestations of the beta-Thalassemias. Cold Spring Harb Perspect Med Dec 1(12):a011726. https:\/\/doi.org\/10.1101\/cshperspect.a011726","journal-title":"Cold Spring Harb Perspect Med Dec"},{"issue":"10116","key":"1756_CR72","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","volume":"13","author":"AT Taher","year":"2018","unstructured":"Taher AT, Weatherall DJ, Cappellini MD (2018) Thalassaemia. Lancet 13(10116):155\u2013167. https:\/\/doi.org\/10.1016\/S0140-6736(17)31822-6","journal-title":"Lancet"},{"issue":"2","key":"1756_CR73","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bcmd.2015.05.011","volume":"55","author":"AT Taher","year":"2015","unstructured":"Taher AT, Musallam KM, Saliba AN, Graziadei G, Cappellini MD (2015) Hemoglobin level and morbidity in non-transfusion-dependent thalassemia. Blood Cells Mol Dis Aug 55(2):108\u2013109. https:\/\/doi.org\/10.1016\/j.bcmd.2015.05.011","journal-title":"Blood Cells Mol Dis Aug"},{"issue":"2","key":"1756_CR74","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1309\/AJCP20UTTCAYKUDX","volume":"138","author":"M Schoorl","year":"2012","unstructured":"Schoorl M, Schoorl M, Linssen J et al (2012) Efficacy of advanced discriminating algorithms for screening on iron-deficiency anemia and beta-thalassemia trait: a multicenter evaluation. Am J Clin Pathol Aug 138(2):300\u2013304. https:\/\/doi.org\/10.1309\/AJCP20UTTCAYKUDX","journal-title":"Am J Clin Pathol Aug"},{"key":"1756_CR75","unstructured":"Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V (2014) Guidelines for the management of Transfusion Dependent Thalassaemia (TDT). (3rd ed)"},{"issue":"5","key":"1756_CR76","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.talanta.2004.09.013","volume":"65","author":"SK Hartwell","year":"2005","unstructured":"Hartwell SK, Srisawang B, Kongtawelert P, Christian GD, Grudpan K (2005) Review on screening and analysis techniques for hemoglobin variants and thalassemia. Talanta. https:\/\/doi.org\/10.1016\/j.talanta.2004.09.013","journal-title":"Talanta"},{"key":"1756_CR77","doi-asserted-by":"crossref","unstructured":"Efremov DG, Dimovski AJ, Efremov GD (1991) Detection of beta-thalassemia mutations by ASO hybridization of PCR amplified DNA with Digoxigenin DdUTP labeled oligonucleotides. PubMed","DOI":"10.3109\/03630269109027900"},{"issue":"6","key":"1756_CR78","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/molehr\/3.6.523","volume":"3","author":"E Kanavakis","year":"1997","unstructured":"Kanavakis E, Traeger-Synodinos J, Vrettou C, Maragoudaki E, Tzetis M, Kattamis C (1997) Prenatal diagnosis of the thalassaemia syndromes by rapid DNA analytical methods. Mol Hum Reprod Jun 3(6):523\u2013528. https:\/\/doi.org\/10.1093\/molehr\/3.6.523","journal-title":"Mol Hum Reprod Jun"},{"issue":"6146","key":"1756_CR79","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/330384a0","volume":"2","author":"C Wong","year":"1987","unstructured":"Wong C, Dowling CE, Saiki RK, Higuchi RG, Erlich HA, Kazazian HH (1987) Jr. Characterization of beta-thalassaemia mutations using direct genomic sequencing of amplified single copy DNA. Nature Nov 26-Dec 2(6146):384\u2013386. https:\/\/doi.org\/10.1038\/330384a0","journal-title":"Nature Nov 26-Dec"},{"key":"1756_CR80","doi-asserted-by":"crossref","unstructured":"Christina V, Joanne TS, Maria T, George M, Emmanuel K (2003) Rapid screening of multiple beta-globin gene mutations by real-time PCR on the lightcycler: application to carrier screening and prenatal diagnosis of thalassemia syndromes. Clin Chem (5):769\u2013776","DOI":"10.1373\/49.5.769"},{"issue":"29","key":"1756_CR81","doi-asserted-by":"publisher","first-page":"10762","DOI":"10.1073\/pnas.0403962101","volume":"20","author":"C Ding","year":"2004","unstructured":"Ding C, Chiu RW, Lau TK et al (2004) MS analysis of single-nucleotide differences in Circulating nucleic acids: application to noninvasive prenatal diagnosis. Proc Natl Acad Sci U S A Jul 20(29):10762\u201310767. https:\/\/doi.org\/10.1073\/pnas.0403962101","journal-title":"Proc Natl Acad Sci U S A Jul"},{"issue":"S1","key":"1756_CR82","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/ijlh.12527","volume":"38","author":"V Brancaleoni","year":"2016","unstructured":"Brancaleoni V, Di Pierro E, Motta I, Cappellini MD (2016) Laboratory diagnosis of thalassemia. Int J Lab Hematol 38(S1):32\u201340. https:\/\/doi.org\/10.1111\/ijlh.12527","journal-title":"Int J Lab Hematol"},{"key":"1756_CR83","unstructured":"Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V (2013) Guidelines for the management of Non Transfusion Dependent Thalassaemia (NTDT). In: Weatherall D, ed"},{"issue":"5","key":"1756_CR84","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1365-2141.2010.08486.x","volume":"152","author":"AT Taher","year":"2011","unstructured":"Taher AT, Musallam KM, Cappellini MD, Weatherall DJ (2011) Optimal management of \u03b2 thalassaemia intermedia. Br J Haematol 152(5):512\u201323. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08486.x","journal-title":"Br J Haematol"},{"issue":"1","key":"1756_CR85","doi-asserted-by":"publisher","first-page":"e2019019","DOI":"10.4084\/MJHID.2019.019","volume":"11","author":"R Origa","year":"2019","unstructured":"Origa R, Comitini F (2019) Pregnancy in thalassemia. Mediterr J Hematol Infect Dis 11(1):e2019019. https:\/\/doi.org\/10.4084\/MJHID.2019.019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1756_CR86","doi-asserted-by":"publisher","unstructured":"Mutar MT, Majid M, Jaleel A, Saad A, Abdulmortafea A, Talib H (2019) Awareness among parents of beta thalassemia major and intermedia patie nts in three centers in Baghdad and Al-Nasiriyah, Iraq in 2017. Int J Med Stud 7(1):6\u201310. https:\/\/doi.org\/10.5195\/ijms.2019.315","DOI":"10.5195\/ijms.2019.315"},{"issue":"5","key":"1756_CR87","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3109\/03630269.2012.699489","volume":"36","author":"R Kumar","year":"2012","unstructured":"Kumar R, Sharma DC, Kishor P (2012) Hb E\/\u03b2-thalassemia: the second most common cause of transfusion-dependent thalassemia in the Gwalior-Chambal region of central India. Hemoglobin 36(5):485\u2013490. https:\/\/doi.org\/10.3109\/03630269.2012.699489","journal-title":"Hemoglobin"},{"issue":"12","key":"1756_CR88","doi-asserted-by":"publisher","first-page":"e1788","DOI":"10.1002\/mgg3.1788","volume":"9","author":"S Ali","year":"2021","unstructured":"Ali S, Mumtaz S, Shakir HA et al (2021) Current status of beta-thalassemia and its treatment strategies. Mol Genet Genomic Med Dec 9(12):e1788. https:\/\/doi.org\/10.1002\/mgg3.1788","journal-title":"Mol Genet Genomic Med Dec"},{"issue":"5","key":"1756_CR89","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1365-2141.2011.08626.x","volume":"154","author":"E Voskaridou","year":"2011","unstructured":"Voskaridou E, Christoulas D, Terpos E (2011) Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol 154(5):654\u2013656. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08626.x","journal-title":"Br J Haematol"},{"issue":"3","key":"1756_CR90","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.4081\/thal.2014.4862","volume":"12\/4","author":"R Origa","year":"2014","unstructured":"Origa R (2014) Combination therapies in iron chelation. Thalassemia Rep 12\/4(3):4862. https:\/\/doi.org\/10.4081\/thal.2014.4862","journal-title":"Thalassemia Rep"},{"key":"1756_CR91","unstructured":"Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V (2014) Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). In: Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, eds. Thalassaemia International Federation (3rd edn)"},{"key":"1756_CR92","unstructured":"Canatan D, Ko N (2004) The effect of transfusion on pulmonary function tests in patients with thalassemia. Turk J Haematol (3)"},{"issue":"1","key":"1756_CR93","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/03630267909069153","volume":"3","author":"R Galanello","year":"1979","unstructured":"Galanello R, Melis MA, Ruggeri R et al (1979) Beta 0 thalassemia trait in Sardinia. Hemoglobin 3(1):33\u201346. https:\/\/doi.org\/10.3109\/03630267909069153","journal-title":"Hemoglobin"},{"issue":"1","key":"1756_CR94","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1182\/blood-2012-12-471441","volume":"4","author":"SR Pasricha","year":"2013","unstructured":"Pasricha SR, Frazer DM, Bowden DK, Anderson GJ (2013) Transfusion suppresses erythropoiesis and increases Hepcidin in adult patients with beta-thalassemia major: a longitudinal study. Blood 4(1):124\u2013133. https:\/\/doi.org\/10.1182\/blood-2012-12-471441","journal-title":"Blood"},{"issue":"1","key":"1756_CR95","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2450\/2019.0229-18","volume":"17","author":"M Franchini","year":"2019","unstructured":"Franchini M, Forni GL, Marano G et al (2019) Red blood cell alloimmunisation in transfusion-dependent thalassaemia: a systematic review. Blood Transfus Jan 17(1):4\u201315. https:\/\/doi.org\/10.2450\/2019.0229-18","journal-title":"Blood Transfus Jan"},{"issue":"10","key":"1756_CR96","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1182\/blood.V96.10.3369","volume":"15","author":"ST Singer","year":"2000","unstructured":"Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP (2000) Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood Nov 15(10):3369\u20133373","journal-title":"Blood Nov"},{"issue":"2","key":"1756_CR97","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.hoc.2017.11.004","volume":"32","author":"KT Carlberg","year":"2018","unstructured":"Carlberg KT, Singer ST, Vichinsky EP (2018) Fertility and pregnancy in women with transfusion-dependent thalassemia. Hematol Oncol Clin North Am 32(2):297\u2013315. https:\/\/doi.org\/10.1016\/j.hoc.2017.11.004","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"1756_CR98","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1160\/th06-05-0267","volume":"96","author":"A Taher","year":"2006","unstructured":"Taher A, Isma\u2019eel H, Mehio G et al (2006) Prevalence of thromboembolic events among 8,860 patients with thalassa emia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 96(10):488\u2013491. https:\/\/doi.org\/10.1160\/th06-05-0267","journal-title":"Thromb Haemost"},{"issue":"1","key":"1756_CR99","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1538-7836.2009.03651.x","volume":"8","author":"AT Taher","year":"2010","unstructured":"Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A (2010) Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost 8(1):54\u201359. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03651.x","journal-title":"J Thromb Haemost"},{"issue":"1","key":"1756_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/vox.12201","volume":"108","author":"AT Taher","year":"2014","unstructured":"Taher AT, Radwan A, Viprakasit V (2014) When to consider transfusion therapy for patients with non-transfusion \u2010dependent thalassaemia. Vox Sang 108(1):1\u201310. https:\/\/doi.org\/10.1111\/vox.12201","journal-title":"Vox Sang"},{"key":"1756_CR101","doi-asserted-by":"crossref","unstructured":"Staikou C, Stavroulakis E, Karmaniolou I\u00a0(2014) A narrative review of peri-operative management of patients with thalassaemia. Anaesthesia 69(5):494\u2013510","DOI":"10.1111\/anae.12591"},{"key":"1756_CR102","unstructured":"Yardumian A, Telfer P, Constantinou G et al (2005) Standards for the Clinical Care of Children and Adults with Thalassaemia in the UK"},{"issue":"3","key":"1756_CR103","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2450\/2012.0072-11","volume":"10","author":"M Kosaryan","year":"2012","unstructured":"Kosaryan M, Mahdavi MR, Roshan P, Hojjati MT (2012) Prevalence of alloimmunisation in patients with beta thalassaemia major. Blood Transfus Jul 10(3):396\u2013397. https:\/\/doi.org\/10.2450\/2012.0072-11","journal-title":"Blood Transfus Jul"},{"issue":"2","key":"1756_CR104","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1046\/j.1537-2995.1997.37297203514.x","volume":"37","author":"M Cazzola","year":"1997","unstructured":"Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P (1997) A moderate transfusion regimen may reduce iron loading in beta\u2010 thalas semia major without producing excessive expansion of erythropoiesis. Transfusion 37(2):135\u2013140. https:\/\/doi.org\/10.1046\/j.1537-2995.1997.37297203514.x","journal-title":"Transfusion"},{"issue":"9","key":"1756_CR105","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1056\/NEJM199409013310903","volume":"1","author":"NF Olivieri","year":"1994","unstructured":"Olivieri NF, Nathan DG, MacMillan JH et al (1994) Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med Sep 1(9):574\u2013578. https:\/\/doi.org\/10.1056\/NEJM199409013310903","journal-title":"N Engl J Med"},{"issue":"2","key":"1756_CR106","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMct1004810","volume":"13","author":"GM Brittenham","year":"2011","unstructured":"Brittenham GM (2011) Iron-chelating therapy for transfusional iron overload. N Engl J Med 13(2):146\u2013156. https:\/\/doi.org\/10.1056\/NEJMct1004810","journal-title":"N Engl J Med"},{"issue":"11","key":"1756_CR107","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/archdischild-2014-308112","volume":"100","author":"A Amid","year":"2015","unstructured":"Amid A, Saliba AN, Taher AT, Klaassen RJ (2015) Thalassaemia in children: from quality of care to quality of life. Arch Dis Child 100(11):1051\u20131057. https:\/\/doi.org\/10.1136\/archdischild-2014-308112","journal-title":"Arch Dis Child"},{"issue":"Suppl 1","key":"1756_CR108","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0268-960X(09)70003-7","volume":"23","author":"JB Porter","year":"2009","unstructured":"Porter JB (2009) Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev Dec 23(Suppl 1):S3\u20137. https:\/\/doi.org\/10.1016\/S0268-960X(09)70003-7","journal-title":"Blood Rev Dec"},{"key":"1756_CR109","unstructured":"Skordis N, Sanctis VD, Soliman A (2014) Endocrine Disease in Thalassemia. In : Guidelines for the management of Transfusion Dependent Thalassaemia (TDT). Guidelines for the management of Transfusion Dependent Thalassaemia (TDT)"},{"issue":"11","key":"1756_CR110","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3324\/haematol.2011.047852","volume":"96","author":"KM Musallam","year":"2011","unstructured":"Musallam KM, Cappellini MD, Wood JC et al (2011) Elevated liver iron concentration is a marker of increased morbidity in patients with \u03b2 thalassemia intermedia. Haematologica 96(11):1605\u20131612. https:\/\/doi.org\/10.3324\/haematol.2011.047852","journal-title":"Haematologica"},{"issue":"10","key":"1756_CR111","first-page":"1187","volume":"89","author":"C Borgna-Pignatti","year":"2004","unstructured":"Borgna-Pignatti C, Rugolotto S, De Stefano P et al (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica Oct 89(10):1187\u20131193","journal-title":"Haematologica Oct"},{"issue":"6","key":"1756_CR112","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2471\/blt.06.036673","volume":"86","author":"B Modell","year":"2008","unstructured":"Modell B, Darlison M (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ Jun 86(6):480\u2013487. https:\/\/doi.org\/10.2471\/blt.06.036673","journal-title":"Bull World Health Organ Jun"},{"issue":"2","key":"1756_CR113","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ajh.23876","volume":"90","author":"DJ Pennell","year":"2015","unstructured":"Pennell DJ, Porter JB, Piga A et al (2015) Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Am J Hematol 90(2):91\u201396. https:\/\/doi.org\/10.1002\/ajh.23876","journal-title":"Am J Hematol"},{"issue":"6","key":"1756_CR114","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3324\/haematol.2011.049957","volume":"97","author":"DJ Pennell","year":"2012","unstructured":"Pennell DJ, Porter JB, Cappellini MD et al (2012) Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with -thalassemia major. Haematologica 97(6):842\u2013848. https:\/\/doi.org\/10.3324\/haematol.2011.049957","journal-title":"Haematologica"},{"issue":"9","key":"1756_CR115","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJM199409013310902","volume":"1","author":"GM Brittenham","year":"1994","unstructured":"Brittenham GM, Griffith PM, Nienhuis AW et al (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1(9):567\u2013573. https:\/\/doi.org\/10.1056\/NEJM199409013310902","journal-title":"N Engl J Med"},{"issue":"11","key":"1756_CR116","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/nejm199009133231104","volume":"323","author":"N Bronspiegel-Weintrob","year":"1990","unstructured":"Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ (1990) Effect of age at the start of iron chelation therapy on gonadal function in \u03b2-Thalassemia Major. N Engl J Med 323(11):713\u2013719. https:\/\/doi.org\/10.1056\/nejm199009133231104","journal-title":"N Engl J Med"},{"key":"1756_CR117","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2147\/DDDT.S79458","volume":"10","author":"CN Kontoghiorghe","year":"2016","unstructured":"Kontoghiorghe CN, Kontoghiorghes GJ (2016) Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther 10:465\u2013481. https:\/\/doi.org\/10.2147\/DDDT.S79458","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"1756_CR118","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta13010","volume":"13","author":"C McLeod","year":"2009","unstructured":"McLeod C, Fleeman N, Kirkham J et al (2009) Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess Jan 13(1):iii\u2013iv. ix-xi10.3310\/hta13010","journal-title":"Health Technol Assess Jan"},{"issue":"1","key":"1756_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5662\/wjm.v6.i1.1","volume":"26","author":"CN Kontoghiorghe","year":"2016","unstructured":"Kontoghiorghe CN, Kontoghiorghes GJ (2016) New developments and controversies in iron metabolism and iron chelation therapy. World J Methodol Mar 26(1):1\u201319. https:\/\/doi.org\/10.5662\/wjm.v6.i1.1","journal-title":"World J Methodol Mar"},{"issue":"Suppl 2","key":"1756_CR120","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/S0268-960X(08)70004-3","volume":"22","author":"JC Wood","year":"2008","unstructured":"Wood JC (2008) Cardiac iron across different transfusion-dependent diseases. Blood Rev Dec 22(Suppl 2):S14\u201321. https:\/\/doi.org\/10.1016\/S0268-960X(08)70004-3","journal-title":"Blood Rev Dec"},{"issue":"6","key":"1756_CR121","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/s2352-3026(20)30100-9","volume":"7","author":"A Maggio","year":"2020","unstructured":"Maggio A, Kattamis A, Felisi M et al (2020) Evaluation of the efficacy and safety of deferiprone compared with def erasirox in paediatric patients with transfusion-dependent haemoglobin opathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematol 7(6):e469\u2013e478. https:\/\/doi.org\/10.1016\/s2352-3026(20)30100-9","journal-title":"Lancet Haematol"},{"issue":"8726","key":"1756_CR122","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/0140-6736(90)92962-h","volume":"24","author":"NF Olivieri","year":"1990","unstructured":"Olivieri NF, Koren G, Hermann C et al (1990) Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 24(8726):1275\u20131279. https:\/\/doi.org\/10.1016\/0140-6736(90)92962-h","journal-title":"Lancet"},{"issue":"9","key":"1756_CR123","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","volume":"1","author":"DJ Pennell","year":"2006","unstructured":"Pennell DJ, Berdoukas V, Karagiorga M et al (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood May 1(9):3738\u20133744. https:\/\/doi.org\/10.1182\/blood-2005-07-2948","journal-title":"Blood May"},{"issue":"4","key":"1756_CR124","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/s0950-3536(05)80131-3","volume":"7","author":"V Gabutti","year":"1994","unstructured":"Gabutti V, Borgna-Pignatti C (1994) Clinical manifestations and therapy of transfusional haemosiderosis. Baillieres Clin Haematol 7(4):919\u2013940. https:\/\/doi.org\/10.1016\/s0950-3536(05)80131-3","journal-title":"Baillieres Clin Haematol"},{"issue":"9","key":"1756_CR125","first-page":"1187","volume":"91","author":"P Telfer","year":"2006","unstructured":"Telfer P, Coen PG, Christou S et al (2006) Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980\u20132004. Haematologica Sep 91(9):1187\u20131192","journal-title":"Haematologica Sep"},{"issue":"3","key":"1756_CR126","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/MOH.0b013e32832990a4","volume":"16","author":"S Rivella","year":"2009","unstructured":"Rivella S (2009) Ineffective erythropoiesis and thalassemias. Curr Opin Hematol 16(3):187\u2013194. https:\/\/doi.org\/10.1097\/MOH.0b013e32832990a4","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"1756_CR127","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.blre.2017.10.001","volume":"32","author":"PR Oikonomidou","year":"2018","unstructured":"Oikonomidou PR, Rivella S (2018) What can we learn from ineffective erythropoiesis in thalassemia? Blood Rev 32(2):130\u2013143. https:\/\/doi.org\/10.1016\/j.blre.2017.10.001","journal-title":"Blood Rev"},{"issue":"2","key":"1756_CR128","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.3324\/haematol.2017.181511","volume":"103","author":"C Casu","year":"2018","unstructured":"Casu C, Presti VL, Oikonomidou PR et al (2018) Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of \u03b2-thalassemia intermedia and major. Haematologica 103(2):e46\u2013e49. https:\/\/doi.org\/10.3324\/haematol.2017.181511","journal-title":"Haematologica"},{"issue":"15","key":"1756_CR129","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"15","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, Vaddi K, Liu P et al (2010) Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 15(15):3109\u20133117. https:\/\/doi.org\/10.1182\/blood-2009-04-214957","journal-title":"Blood"},{"issue":"4","key":"1756_CR130","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","volume":"62","author":"TYJ Appeldoorn","year":"2023","unstructured":"Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL-d, Touw DJ (2023) Pharmacokinetics and pharmacodynamics of ruxolitinib: a review. Clin Pharmacokinet 62(4):559\u2013571. https:\/\/doi.org\/10.1007\/s40262-023-01225-7","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1756_CR131","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1111\/bcp.14918","volume":"88","author":"L Grech","year":"2021","unstructured":"Grech L, Borg K, Borg J (2021) Novel therapies in \u03b2-thalassaemia. Brit J Clinical Pharma 88(6):2509\u20132524. https:\/\/doi.org\/10.1111\/bcp.14918","journal-title":"Brit J Clinical Pharma"},{"issue":"2","key":"1756_CR132","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1182\/blood-2017-06-790121","volume":"11","author":"AT Taher","year":"2018","unstructured":"Taher AT, Karakas Z, Cassinerio E et al (2018) Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood 11(2):263\u2013265. https:\/\/doi.org\/10.1182\/blood-2017-06-790121","journal-title":"Blood"},{"issue":"20","key":"1756_CR133","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1089\/scd.2013.0008","volume":"15","author":"H Bai","year":"2013","unstructured":"Bai H, Xie YL, Gao YX, Cheng T, Wang ZZ (2013) The balance of positive and negative effects of TGF-beta signaling regulates the development of hematopoietic and endothelial progenitors in human pluripotent stem cells. Stem Cells Dev Oct 15(20):2765\u20132776. https:\/\/doi.org\/10.1089\/scd.2013.0008","journal-title":"Stem Cells Dev Oct"},{"issue":"2","key":"1756_CR134","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/leu.2017.198","volume":"32","author":"CY Zhang","year":"2018","unstructured":"Zhang CY, Yin HM, Wang H et al (2018) Transforming growth factor-\u03b21 regulates the nascent hematopoietic stem cell niche by promoting gluconeogenesis. Leukemia 32(2):479\u2013491. https:\/\/doi.org\/10.1038\/leu.2017.198","journal-title":"Leukemia"},{"issue":"3","key":"1756_CR135","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.stem.2010.02.002","volume":"5","author":"GA Challen","year":"2010","unstructured":"Challen GA, Boles NC, Chambers SM, Goodell MA (2010) Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell Mar 5(3):265\u2013278. https:\/\/doi.org\/10.1016\/j.stem.2010.02.002","journal-title":"Cell Stem Cell Mar"},{"issue":"12","key":"1756_CR136","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1002\/jcb.25233","volume":"116","author":"Y Xie","year":"2015","unstructured":"Xie Y, Bai H, Liu Y, Hoyle DL, Cheng T, Wang ZZ (2015) Cooperative effect of erythropoietin and TGF-beta Inhibition on erythroid development in human pluripotent stem cells. J Cell Biochem Dec 116(12):2735\u20132743. https:\/\/doi.org\/10.1002\/jcb.25233","journal-title":"J Cell Biochem Dec"},{"issue":"7","key":"1756_CR137","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1358\/dot.2020.56.7.3159184","volume":"56","author":"F Pilo","year":"2020","unstructured":"Pilo F, Angelucci E (2020) Luspatercept to treat beta-thalassemia. Drugs Today (Barc) 56(7):447\u2013458. https:\/\/doi.org\/10.1358\/dot.2020.56.7.3159184","journal-title":"Drugs Today (Barc)"},{"issue":"3","key":"1756_CR138","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3324\/haematol.2018.198887","volume":"104","author":"MD Cappellini","year":"2019","unstructured":"Cappellini MD, Porter J, Origa R et al (2019) Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: a phase II, open-label, dose-finding study. Haematologica Mar 104(3):477\u2013484. https:\/\/doi.org\/10.3324\/haematol.2018.198887","journal-title":"Haematologica Mar"},{"issue":"10","key":"1756_CR139","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1111\/j.1538-7836.2010.03940.x","volume":"8","author":"AT Taher","year":"2010","unstructured":"Taher AT, Musallam KM, Karimi M et al (2010) Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost 8(10):2152\u20132158. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03940.x","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1756_CR140","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2141.2008.07126.x","volume":"141","author":"NF Olivieri","year":"2008","unstructured":"Olivieri NF, Muraca GM, O\u2019Donnell A, Premawardhena A, Fisher C, Weatherall DJ (2008) Studies in haemoglobin E beta-thalassaemia. Br J Haematol May 141(3):388\u2013397. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07126.x","journal-title":"Br J Haematol May"},{"issue":"9","key":"1756_CR141","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/ajh.22102","volume":"86","author":"A Piga","year":"2011","unstructured":"Piga A, Serra M, Longo F et al (2011) Changing patterns of splenectomy in transfusion-dependent thalassemia patients. Am J Hematol 86(9):808\u2013810. https:\/\/doi.org\/10.1002\/ajh.22102","journal-title":"Am J Hematol"},{"issue":"12","key":"1756_CR142","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2012-10-408021","volume":"21","author":"KM Musallam","year":"2013","unstructured":"Musallam KM, Taher AT, Cappellini MD, Sankaran VG (2013) Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia. Blood 21(12):2199\u20132212. https:\/\/doi.org\/10.1182\/blood-2012-10-408021","journal-title":"Blood"},{"issue":"1","key":"1756_CR143","doi-asserted-by":"publisher","first-page":"48","DOI":"10.22631\/ijbmph.2018.56102","volume":"1","author":"K Tari","year":"2018","unstructured":"Tari K, Valizadeh Ardalan P, Abbaszadehdibavar M, Atashi A, Jalili A, Gheidishahran M (2018) Thalassemia an update: molecular basis, clinical features and treatment. IJBMPH 1(1):48\u201358. https:\/\/doi.org\/10.22631\/ijbmph.2018.56102","journal-title":"IJBMPH"},{"issue":"10","key":"1756_CR144","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2010-08-300723","volume":"117","author":"A Wilber","year":"2011","unstructured":"Wilber A, Hargrove PW, Kim Y-S et al (2011) Therapeutic levels of fetal hemoglobin in erythroid progeny of \u03b2-thala Ssemic CD34\u2009+\u2009cells after lentiviral vector-mediated gene transfer. Blood 117(10):2817\u20132826. https:\/\/doi.org\/10.1182\/blood-2010-08-300723","journal-title":"Blood"},{"key":"1756_CR145","doi-asserted-by":"publisher","unstructured":"Gambari R, Finotti A, Breda L, et al (2015) Recent trends in the gene therapy of \u03b2-thalassemia. JBM. 69. https:\/\/doi.org\/10.2147\/jbm.s46256","DOI":"10.2147\/jbm.s46256"},{"issue":"8","key":"1756_CR146","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1177\/1535370215596859","volume":"240","author":"BS Pace","year":"2015","unstructured":"Pace BS, Liu L, Li B, Makala LH (2015) Cell signaling pathways involved in drug-mediated fetal hemoglobin ind uction: Strategies to treat sickle cell disease. Exp Biol Med 240(8):1050\u20131064. https:\/\/doi.org\/10.1177\/1535370215596859","journal-title":"Exp Biol Med"},{"issue":"8","key":"1756_CR147","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12098-017-2325-1","volume":"84","author":"VP Choudhry","year":"2017","unstructured":"Choudhry VP (2017) Thalassemia minor and major: current management. Indian J Pediatr 84(8):607\u2013611. https:\/\/doi.org\/10.1007\/s12098-017-2325-1","journal-title":"Indian J Pediatr"},{"issue":"10","key":"1756_CR148","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1016\/s2352-3026(18)30162-5","volume":"5","author":"H The Lancet","year":"2018","unstructured":"The Lancet H (2018) Beta-thalassaemia: all roads lead to a cure? Lancet Haematol 5(10):e430. https:\/\/doi.org\/10.1016\/s2352-3026(18)30162-5","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"1756_CR149","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1038\/bmt.2008.124","volume":"42","author":"M Chandy","year":"2008","unstructured":"Chandy M (2008) Stem cell transplantation in India. Bone Marrow Transplant 42(Suppl 1):S81\u2013S84. https:\/\/doi.org\/10.1038\/bmt.2008.124","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1756_CR150","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/bmt.2015.293","volume":"51","author":"D Baronciani","year":"2016","unstructured":"Baronciani D, Angelucci E, Potschger U et al (2016) Hemopoietic stem cell transplantation in thalassemia: a report from the European society for blood and bone marrow transplantation hemoglobinopathy registry, 2000\u20132010. Bone Marrow Transplant 51(4):536\u2013541. https:\/\/doi.org\/10.1038\/bmt.2015.293","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"1756_CR151","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2013.099747","volume":"99","author":"E Angelucci","year":"2014","unstructured":"Angelucci E, Matthes-Martin S, Baronciani D et al (2014) Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 99(5):811\u2013820. https:\/\/doi.org\/10.3324\/haematol.2013.099747","journal-title":"Haematologica"},{"issue":"6","key":"1756_CR152","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/MOH.0000000000000280","volume":"23","author":"F Locatelli","year":"2016","unstructured":"Locatelli F, Merli P, Strocchio L (2016) Transplantation for thalassemia major: alternative donors. Curr Opin Hematol 23(6):515\u2013523. https:\/\/doi.org\/10.1097\/MOH.0000000000000280","journal-title":"Curr Opin Hematol"},{"key":"1756_CR153","doi-asserted-by":"publisher","first-page":"104624","DOI":"10.1016\/j.amsu.2022.104624","volume":"82","author":"AA Asghar","year":"2022","unstructured":"Asghar AA, Khabir Y, Hashmi MR (2022) Zynteglo: betibeglogene autotemcel - An innovative therapy for beta- thalassemia patients. Ann Med Surg (Lond) Oct 82:104624. https:\/\/doi.org\/10.1016\/j.amsu.2022.104624","journal-title":"Ann Med Surg (Lond) Oct"},{"issue":"23","key":"1756_CR154","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1056\/NEJMc2103481","volume":"10","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, Ho TW, Corbacioglu S (2021) CRISPR-Cas9 gene editing for sickle cell disease and beta-Thalassemia. Reply. N Engl J Med Jun 10(23):e91. https:\/\/doi.org\/10.1056\/NEJMc2103481","journal-title":"N Engl J Med Jun"},{"issue":"5","key":"1756_CR155","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/2040620716653729","volume":"7","author":"MA Goodman","year":"2016","unstructured":"Goodman MA, Malik P (2016) The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges. Ther Adv Hematol 7(5):302\u2013315. https:\/\/doi.org\/10.1177\/2040620716653729","journal-title":"Ther Adv Hematol"},{"key":"1756_CR156","doi-asserted-by":"publisher","unstructured":"Laurent M, Geoffroy M, Pavani G, Guiraud S (2024) CRISPR-based gene therapies: from preclinical to clinical treatments. Cells\u00a013(10). https:\/\/doi.org\/10.3390\/cells13100800","DOI":"10.3390\/cells13100800"},{"key":"1756_CR157","doi-asserted-by":"publisher","first-page":"e944204","DOI":"10.12659\/MSM.944204","volume":"1","author":"DV Parums","year":"2024","unstructured":"Parums DV, Editorial (2024) First regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and Transfusion-Dependent beta-Thalassemia. Med Sci Monit Mar 1:30:e944204. https:\/\/doi.org\/10.12659\/MSM.944204","journal-title":"Med Sci Monit Mar"},{"issue":"3","key":"1756_CR158","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1365-2141.2006.06408.x","volume":"136","author":"L Quek","year":"2007","unstructured":"Quek L, Thein SL (2007) Molecular therapies in beta-thalassaemia. Br J Haematol Feb 136(3):353\u2013365. https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06408.x","journal-title":"Br J Haematol Feb"},{"issue":"6155","key":"1756_CR159","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1126\/science.1242088","volume":"342","author":"DE Bauer","year":"2013","unstructured":"Bauer DE, Kamran SC, Lessard S et al (2013) An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science. https:\/\/doi.org\/10.1126\/science.1242088","journal-title":"Science"},{"key":"1756_CR160","doi-asserted-by":"publisher","unstructured":"de la Fuente J, Frangoul H, Lang P et al (2025) Improvements in health-related quality of life in patients with transfusion-dependent beta-thalassemia after exagamglogene autotemcel. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2025016702","DOI":"10.1182\/bloodadvances.2025016702"},{"issue":"18","key":"1756_CR161","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","volume":"9","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Lang P, Wall D et al (2024) Exagamglogene autotemcel for Transfusion-Dependent beta-Thalassemia. N Engl J Med May 9(18):1663\u20131676. https:\/\/doi.org\/10.1056\/NEJMoa2309673","journal-title":"N Engl J Med May"},{"issue":"3","key":"1756_CR162","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"21","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD et al (2021) CRISPR-Cas9 gene editing for sickle cell disease and beta-Thalassemia. N Engl J Med Jan 21(3):252\u2013260. https:\/\/doi.org\/10.1056\/NEJMoa2031054","journal-title":"N Engl J Med"},{"key":"1756_CR163","unstructured":"Incorporated VP, Accessed (2024)\u00a0https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-us-fda-approval-casgevytm-exagamglogene"},{"issue":"5","key":"1756_CR164","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa2113206","volume":"3","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, Thompson AA, Kwiatkowski JL et al (2022) Betibeglogene autotemcel gene therapy for Non-beta(0)\/beta(0) genotype beta-Thalassemia. N Engl J Med Feb 3(5):415\u2013427. https:\/\/doi.org\/10.1056\/NEJMoa2113206","journal-title":"N Engl J Med Feb"},{"issue":"10468","key":"1756_CR165","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/S0140-6736(24)01884-1","volume":"404","author":"JL Kwiatkowski","year":"2024","unstructured":"Kwiatkowski JL, Walters MC, Hongeng S et al (2024) Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype \u03b2-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(24)01884-1","journal-title":"Lancet"},{"issue":"1","key":"1756_CR166","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/bloodadvances.2024014104","volume":"14","author":"A Mirza","year":"2025","unstructured":"Mirza A, Ritsert ML, Tao G et al (2025) Gene therapy in transfusion-dependent non-beta0\/beta0 genotype beta-thalassemia: first real-world experience of beti-cel. Blood Adv Jan 14(1):29\u201338. https:\/\/doi.org\/10.1182\/bloodadvances.2024014104","journal-title":"Blood Adv Jan"},{"key":"1756_CR167","doi-asserted-by":"publisher","unstructured":"Kwiatkowski JL, Walters MC, Hongeng S, et al (2020) Long-term efficacy and safety of betibeglogene autotemcel gene therapy for the treatment of transfusion-dependent \u03b2-thalassemia: results in patients with up to 6 years of follow-up. Blood 136(Supplement 1):51\u201352. https:\/\/doi.org\/10.1182\/blood-2020-135850","DOI":"10.1182\/blood-2020-135850"},{"key":"1756_CR168","doi-asserted-by":"publisher","unstructured":"Kwiatkowski JL, Olson TS, Walters MC, et al (2023) Improvement in Iron Burden in Patients with Transfusion-Dependent \u03b2-Th alassemia (TDT) Treated with Betibeglogene Autotemcel (Beti-cel) Gene therapy: up to 9 years of follow-up. Blood 142(Supplement 1):2480\u20132480. https:\/\/doi.org\/10.1182\/blood-2023-173869","DOI":"10.1182\/blood-2023-173869"},{"key":"1756_CR169","unstructured":"Zynteglo (autologous cd34\u2009+\u2009cells encoding \u03b2AT87Q-globin gene) Dispersion for infusion. (2019) https:\/\/d1ycet1k7mjw9o.cloudfront.net\/attachments\/b\/a\/f\/65e7e7b654f70b62f49f153a691a0.pdf"},{"issue":"2","key":"1756_CR170","doi-asserted-by":"publisher","first-page":"101271","DOI":"10.1016\/j.omtm.2024.101271","volume":"32","author":"S Ellison","year":"2024","unstructured":"Ellison S, Buckland K, Learmonth Y et al (2024) Design and validation of a GMP stem cell manufacturing protocol for MPSII hematopoietic stem cell gene therapy. Mol Ther 32(2):101271. https:\/\/doi.org\/10.1016\/j.omtm.2024.101271","journal-title":"Mol Ther"},{"issue":"5","key":"1756_CR171","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ymthe.2024.03.005","volume":"1","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Cavazzana M, Frangoul H, Fuente J, Algeri M, Meisel R (2024) Autologous gene therapy for hemoglobinopathies: from bench to patient\u2019s bedside. Mol Ther 1(5):1202\u20131218. https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.005","journal-title":"Mol Ther"},{"issue":"12","key":"1756_CR172","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jcyt.2023.05.006","volume":"25","author":"FA Ros","year":"2023","unstructured":"Ros FA, Couto SCF, Milhomens J et al (2023) A systematic review of clinical trials for gene therapies for \u03b2-hemoglobinopathy around the world. Cytotherapy 25(12):1300\u20131306. https:\/\/doi.org\/10.1016\/j.jcyt.2023.05.006","journal-title":"Cytotherapy"},{"key":"1756_CR173","unstructured":"Guidelines for the Management of Transfusion-Dependent \u03b2-Thalassaemia (5th edition). Thalassaemia International Federation. https:\/\/thalassaemia.org.cy\/publications\/tif-publications\/guidelines-for-the-management-of-transfusion-dependent-%CE%B2-thalassaemia-5th-edition-2025\/"},{"key":"1756_CR174","doi-asserted-by":"publisher","unstructured":"Thompson AA, Locatelli F, Yannaki E, et al (2021) Restoring iron homeostasis in Pts who achieved transfusion independenc e after treatment with betibeglogene autotemcel gene therapy: results from up to 7 years of follow-up. Blood 138(Supplement 1):573\u2013573. https:\/\/doi.org\/10.1182\/blood-2021-148177","DOI":"10.1182\/blood-2021-148177"},{"issue":"4","key":"1756_CR175","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.molmed.2024.12.001","volume":"31","author":"G Hardouin","year":"2025","unstructured":"Hardouin G, Miccio A, Brusson M (2025) Gene therapy for beta-thalassemia: current and future options. Trends Mol Med Apr 31(4):344\u2013358. https:\/\/doi.org\/10.1016\/j.molmed.2024.12.001","journal-title":"Trends Mol Med Apr"},{"key":"1756_CR176","doi-asserted-by":"crossref","unstructured":"Lai Y, Liu R, Wang L, Ma XK, Li Y, Yang G, Shi L, Wei J, Wei Z, Zhou X, Lan K, Zhang Y, Mou X, Yang L, Chen J(2024) Rapid, Efficient and Durable Fetal Hemoglobin Production Following CS-101 Treatment in transfusion-dependent \u03b2-thalassemia participants: an autologous, ex vivo edited CD34\u2009+\u2009Stem cell product using the innovative transformer base editor (tBE), 4962 .\u00a0https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper200691.html","DOI":"10.1182\/blood-2024-200691"},{"issue":"17","key":"1756_CR177","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1182\/blood.2023019922","volume":"141","author":"CL Sweeney","year":"2023","unstructured":"Sweeney CL, De Ravin SS (2023) The promise of in vivo HSC prime editing. Blood. https:\/\/doi.org\/10.1182\/blood.2023019922","journal-title":"Blood"},{"issue":"4","key":"1756_CR178","doi-asserted-by":"publisher","first-page":"102371","DOI":"10.1016\/j.omtn.2024.102371","volume":"10","author":"C Shao","year":"2024","unstructured":"Shao C, Liu Q, Xu J et al (2024) Efficient and in situ correction of hemoglobin constant spring mutation by prime editing in human hematopoietic cells. Mol Ther Nucleic Acids Dec 10(4):102371. https:\/\/doi.org\/10.1016\/j.omtn.2024.102371","journal-title":"Mol Ther Nucleic Acids Dec"},{"issue":"1","key":"1756_CR179","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41467-022-35508-7","volume":"14","author":"J Liao","year":"2023","unstructured":"Liao J, Chen S, Hsiao S et al (2023) Therapeutic adenine base editing of human hematopoietic stem cells. Nat Commun (1):207. https:\/\/doi.org\/10.1038\/s41467-022-35508-7","journal-title":"Nat Commun"},{"issue":"4","key":"1756_CR180","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-020-0790-y","volume":"26","author":"J Zeng","year":"2020","unstructured":"Zeng J, Wu Y, Ren C et al (2020) Therapeutic base editing of human hematopoietic stem cells. Nat Med 26(4):535\u2013541. https:\/\/doi.org\/10.1038\/s41591-020-0790-y","journal-title":"Nat Med"},{"key":"1756_CR181","doi-asserted-by":"publisher","unstructured":"Xu S, Liang D, Wang Q et al (2025) In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery. Nat Biomed Eng\u00a0https:\/\/doi.org\/10.1038\/s41551-025-01480-y","DOI":"10.1038\/s41551-025-01480-y"},{"issue":"5","key":"1756_CR182","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G (2019) Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 18(5):358\u2013378. https:\/\/doi.org\/10.1038\/s41573-019-0012-9","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1756_CR183","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"3","author":"JH Wang","year":"2024","unstructured":"Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G (2024) Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther Apr 3(1):78. https:\/\/doi.org\/10.1038\/s41392-024-01780-w","journal-title":"Signal Transduct Target Ther Apr"},{"issue":"3","key":"1756_CR184","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","volume":"37","author":"M Arjomandnejad","year":"2023","unstructured":"Arjomandnejad M, Dasgupta I, Flotte TR, Keeler AM (2023) Immunogenicity of recombinant adeno-associated virus (AAV) vectors for gene transfer. BioDrugs 37(3):311\u2013329. https:\/\/doi.org\/10.1007\/s40259-023-00585-7","journal-title":"BioDrugs"},{"issue":"7","key":"1756_CR185","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","volume":"26","author":"C Leborgne","year":"2020","unstructured":"Leborgne C, Barbon E, Alexander JM et al (2020) IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med 26(7):1096\u20131101. https:\/\/doi.org\/10.1038\/s41591-020-0911-7","journal-title":"Nat Med"},{"issue":"5858","key":"1756_CR186","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1126\/science.1151526","volume":"318","author":"J Yu","year":"2007","unstructured":"Yu J, Vodyanik MA, Smuga-Otto K et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science. https:\/\/doi.org\/10.1126\/science.1151526","journal-title":"Science"},{"issue":"3","key":"1756_CR187","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.stemcr.2020.07.009","volume":"8","author":"ML Tursky","year":"2020","unstructured":"Tursky ML, Loi TH, Artuz CM et al (2020) Direct comparison of four hematopoietic differentiation methods from human induced pluripotent stem cells. Stem Cell Reports 8(3):735\u2013748. https:\/\/doi.org\/10.1016\/j.stemcr.2020.07.009","journal-title":"Stem Cell Reports"},{"issue":"12","key":"1756_CR188","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00439-023-02610-9","volume":"142","author":"SJ Zeng","year":"2023","unstructured":"Zeng SJ, Lei SY, Qu C, Wang Y, Teng SZ, Huang P (2023) CRISPR\/Cas-based gene editing in therapeutic strategies for beta-thalassemia. Hum Genet 142(12):1677\u20131703. https:\/\/doi.org\/10.1007\/s00439-023-02610-9","journal-title":"Hum Genet"},{"issue":"4","key":"1756_CR189","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/sctm.16-0121","volume":"6","author":"P Phanthong","year":"2017","unstructured":"Phanthong P, Borwornpinyo S, Kitiyanant N et al (2017) Enhancement of beta-Globin gene expression in thalassemic IVS2-654 induced pluripotent stem Cell-Derived erythroid cells by modified U7 SnRNA. Stem Cells Transl Med Apr 6(4):1059\u20131069. https:\/\/doi.org\/10.1002\/sctm.16-0121","journal-title":"Stem Cells Transl Med Apr"},{"issue":"1","key":"1756_CR190","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13287-022-02768-5","volume":"7","author":"L Li","year":"2022","unstructured":"Li L, Yi H, Liu Z et al (2022) Genetic correction of concurrent alpha- and beta-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology. Stem Cell Res Ther Mar 7(1):102. https:\/\/doi.org\/10.1186\/s13287-022-02768-5","journal-title":"Stem Cell Res Ther Mar"},{"issue":"1","key":"1756_CR191","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13287-020-01765-w","volume":"16","author":"Y Xian","year":"2020","unstructured":"Xian Y, Xie Y, Song B et al (2020) The safety and effectiveness of genetically corrected iPSCs derived from beta-thalassaemia patients in nonmyeloablative beta-thalassaemic mice. Stem Cell Res Ther Jul 16(1):288. https:\/\/doi.org\/10.1186\/s13287-020-01765-w","journal-title":"Stem Cell Res Ther Jul"},{"key":"1756_CR192","unstructured":"Shi-Qi Z, Feng L, University CM, Neurobiology DO (2017) Research advances in induced pluripotent stem cells in Alzheimer\u2019s disease. Chin J Tissue Eng Res"},{"issue":"9","key":"1756_CR193","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1101\/gr.173427.114","volume":"24","author":"F Xie","year":"2014","unstructured":"Xie F, Ye L, Chang JC et al (2014) Seamless gene correction of \u03b2-thalassemia mutations in patient-specific iPSCs using CRISPR\/Cas9 and piggyBac. Genome Res 24(9):1526\u20131533. https:\/\/doi.org\/10.1101\/gr.173427.114","journal-title":"Genome Res"},{"issue":"2","key":"1756_CR194","doi-asserted-by":"publisher","first-page":"267","DOI":"10.5966\/sctm.2015-0157erratum","volume":"5","author":"Y Yang","year":"2016","unstructured":"Yang Y, Zhang X, Yi L et al (2016) Naive induced pluripotent stem cells generated from beta-Thalassemia fibroblasts allow efficient gene correction with CRISPR\/Cas9. Stem Cells Transl Med Feb 5(2):267. https:\/\/doi.org\/10.5966\/sctm.2015-0157erratum","journal-title":"Stem Cells Transl Med Feb"},{"issue":"48","key":"1756_CR195","doi-asserted-by":"publisher","first-page":"34671","DOI":"10.1074\/jbc.M113.496174","volume":"29","author":"N Ma","year":"2013","unstructured":"Ma N, Liao B, Zhang H et al (2013) Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free beta-thalassemia induced pluripotent stem cells. J Biol Chem Nov 29(48):34671\u201334679. https:\/\/doi.org\/10.1074\/jbc.M113.496174","journal-title":"J Biol Chem Nov"},{"key":"1756_CR196","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omtn.2016.11.010","volume":"17","author":"Y Liu","year":"2017","unstructured":"Liu Y, Yang Y, Kang X et al (2017) One-Step biallelic and scarless correction of a beta-Thalassemia mutation in Patient-Specific iPSCs without drug selection. Mol Ther Nucleic Acids Mar 17:6:57\u201367. https:\/\/doi.org\/10.1016\/j.omtn.2016.11.010","journal-title":"Mol Ther Nucleic Acids Mar"},{"issue":"1","key":"1756_CR197","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13287-018-0779-3","volume":"26","author":"M Wattanapanitch","year":"2018","unstructured":"Wattanapanitch M, Damkham N, Potirat P et al (2018) One-step genetic correction of hemoglobin E\/beta-thalassemia patient-derived iPSCs by the CRISPR\/Cas9 system. Stem Cell Res Ther 26(1):46. https:\/\/doi.org\/10.1186\/s13287-018-0779-3","journal-title":"Stem Cell Res Ther"},{"key":"1756_CR198","doi-asserted-by":"publisher","first-page":"32463","DOI":"10.1038\/srep32463","volume":"6","author":"Z Ou","year":"2016","unstructured":"Ou Z, Niu X, He W et al (2016) The combination of CRISPR\/Cas9 and iPSC technologies in the gene therapy of human beta-thalassemia in mice. Sci Rep Sep 1 6:32463. https:\/\/doi.org\/10.1038\/srep32463","journal-title":"Sci Rep Sep 1"},{"issue":"12","key":"1756_CR199","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/sctm.20-0247","volume":"9","author":"S Demirci","year":"2020","unstructured":"Demirci S, Leonard A, Tisdale JF (2020) Hematopoietic stem cells from pluripotent stem cells: clinical potential, challenges, and future perspectives. Stem Cells Transl Med 9(12):1549\u20131557. https:\/\/doi.org\/10.1002\/sctm.20-0247","journal-title":"Stem Cells Transl Med"},{"key":"1756_CR200","doi-asserted-by":"publisher","first-page":"101600","DOI":"10.1016\/j.scr.2019.101600","volume":"41","author":"JP Ruiz","year":"2019","unstructured":"Ruiz JP, Chen G, Haro Mora JJ et al (2019) Robust generation of erythroid and multilineage hematopoietic progenitors from human iPSCs using a scalable monolayer culture system. Stem Cell Res 41:101600. https:\/\/doi.org\/10.1016\/j.scr.2019.101600","journal-title":"Stem Cell Res"},{"key":"1756_CR201","doi-asserted-by":"publisher","DOI":"10.3390\/cells12020321","author":"J Ding","year":"2023","unstructured":"Ding J, Li Y, Larochelle A (2023) De novo generation of human hematopoietic stem cells from pluripotent stem cells for cellular therapy. Cells. https:\/\/doi.org\/10.3390\/cells12020321","journal-title":"Cells"},{"issue":"7","key":"1756_CR202","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/stmcls\/sxad040","volume":"41","author":"Y Li","year":"2023","unstructured":"Li Y, Ding J, Araki D, Zou J, Larochelle A (2023) Modulation of WNT, Activin\/Nodal, and MAPK signaling pathways increases arterial hemogenic endothelium and hematopoietic stem\/progenitor cell formation during human iPSC differentiation. Stem Cells. https:\/\/doi.org\/10.1093\/stmcls\/sxad040","journal-title":"Stem Cells"},{"issue":"10","key":"1756_CR203","doi-asserted-by":"publisher","first-page":"102641","DOI":"10.1016\/j.stemcr.2025.102641","volume":"20","author":"R Wellington","year":"2025","unstructured":"Wellington R, Cheng X, Dutta S et al (2025) Developmental regulation of endothelial-to-hematopoietic transition from induced pluripotent stem cells. Stem Cell Reports 102641. https:\/\/doi.org\/10.1016\/j.stemcr.2025.102641","journal-title":"Stem Cell Reports"},{"issue":"6","key":"1756_CR204","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/stmcls\/sxac020","volume":"22","author":"MS Poetsch","year":"2022","unstructured":"Poetsch MS, Strano A, Guan K (2022) Human induced pluripotent stem cells: from cell origin, genomic stability, and epigenetic memory to translational medicine. Stem Cells 22(6):546\u2013555. https:\/\/doi.org\/10.1093\/stmcls\/sxac020","journal-title":"Stem Cells"},{"key":"1756_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061470","author":"G Scesa","year":"2021","unstructured":"Scesa G, Adami R, Bottai D (2021) iPSC preparation and epigenetic memory: does the tissue origin matter? Cells. https:\/\/doi.org\/10.3390\/cells10061470","journal-title":"Cells"},{"issue":"3","key":"1756_CR206","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00441-025-03952-8","volume":"399","author":"A Diane","year":"2025","unstructured":"Diane A, Mu UMRBA, Al-Siddiqi HH (2025) Epigenetic memory as crucial contributing factor in directing the differentiation of human iPSC into pancreatic beta-cells in vitro. Cell Tissue Res Mar 399(3):267\u2013276. https:\/\/doi.org\/10.1007\/s00441-025-03952-8","journal-title":"Cell Tissue Res Mar"},{"issue":"9","key":"1756_CR207","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/stcltm\/szae047","volume":"10","author":"D Terheyden-Keighley","year":"2024","unstructured":"Terheyden-Keighley D, Huhne M, Berger T et al (2024) GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy. Stem Cells Transl Med Sep 10(9):898\u2013911. https:\/\/doi.org\/10.1093\/stcltm\/szae047","journal-title":"Stem Cells Transl Med Sep"},{"issue":"1","key":"1756_CR208","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13287-024-03785-2","volume":"15","author":"M Ackermann","year":"2024","unstructured":"Ackermann M, Saleh F, Abdin SM et al (2024) Standardized generation of human iPSC-derived hematopoietic organoids and macrophages utilizing a benchtop bioreactor platform under fully defined conditions. Stem Cell Res Ther (1):171. https:\/\/doi.org\/10.1186\/s13287-024-03785-2","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"1756_CR209","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41596-021-00654-7","volume":"17","author":"M Ackermann","year":"2022","unstructured":"Ackermann M, Rafiei Hashtchin A, Manstein F et al (2022) Continuous human iPSC-macrophage mass production by suspension culture in stirred tank bioreactors. Nat Protoc 17(2):513\u2013539. https:\/\/doi.org\/10.1038\/s41596-021-00654-7","journal-title":"Nat Protoc"},{"key":"1756_CR210","doi-asserted-by":"publisher","first-page":"662360","DOI":"10.3389\/fimmu.2021.662360","volume":"12","author":"C Flahou","year":"2021","unstructured":"Flahou C, Morishima T, Takizawa H, Sugimoto N (2021) Fit-for-all iPSC-derived cell therapies and their evaluation in humanized mice with NK cell immunity. Front Immunol 12:662360. https:\/\/doi.org\/10.3389\/fimmu.2021.662360","journal-title":"Front Immunol"},{"issue":"10","key":"1756_CR211","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41587-019-0227-7","volume":"37","author":"T Deuse","year":"2019","unstructured":"Deuse T, Hu X, Agbor-Enoh S et al (2019) De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans. Nat Biotechnol 37(10):1137\u20131144. https:\/\/doi.org\/10.1038\/s41587-019-0227-7","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1756_CR212","doi-asserted-by":"publisher","first-page":"7698","DOI":"10.1038\/s41467-024-51974-7","volume":"4","author":"S Sun","year":"2024","unstructured":"Sun S, Motazedian A, Li JY et al (2024) Efficient generation of human NOTCH ligand-expressing haemogenic endothelial cells as infrastructure for in vitro haematopoiesis and lymphopoiesis. Nat Commun 4(1):7698. https:\/\/doi.org\/10.1038\/s41467-024-51974-7","journal-title":"Nat Commun"},{"issue":"1","key":"1756_CR213","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-018-04134-7","volume":"8","author":"GI Uenishi","year":"2018","unstructured":"Uenishi GI, Jung HS, Kumar A et al (2018) NOTCH signaling specifies arterial-type definitive hemogenic endothelium from human pluripotent stem cells. Nat Commun 8(1):1828. https:\/\/doi.org\/10.1038\/s41467-018-04134-7","journal-title":"Nat Commun"},{"issue":"1","key":"1756_CR214","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ncrna.2020.12.002","volume":"6","author":"S Ghafouri-Fard","year":"2021","unstructured":"Ghafouri-Fard S, Niazi V, Taheri M (2021) Role of miRNAs and lncRNAs in hematopoietic stem cell differentiation. Non-coding RNA Res 6(1):8\u201314. https:\/\/doi.org\/10.1016\/j.ncrna.2020.12.002","journal-title":"Non-coding RNA Res"},{"issue":"1","key":"1756_CR215","doi-asserted-by":"publisher","first-page":"100939","DOI":"10.1016\/j.crmeth.2024.100939","volume":"27","author":"X Wang","year":"2025","unstructured":"Wang X, Jin Z, Shi Y, Xi R (2025) Detecting copy-number alterations from single-cell chromatin sequencing data by AtaCNA. Cell Rep Methods Jan 27(1):100939. https:\/\/doi.org\/10.1016\/j.crmeth.2024.100939","journal-title":"Cell Rep Methods Jan"},{"issue":"3","key":"1756_CR216","doi-asserted-by":"publisher","first-page":"100806","DOI":"10.1016\/j.xgen.2025.100806","volume":"12","author":"M Chen","year":"2025","unstructured":"Chen M (2025) Capturing cell-type-specific activities of cis-regulatory elements from peak-based single-cell ATAC-seq. Cell Genom Mar 12(3):100806. https:\/\/doi.org\/10.1016\/j.xgen.2025.100806","journal-title":"Cell Genom Mar"},{"issue":"11","key":"1756_CR217","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.jcyt.2024.05.022","volume":"26","author":"M Madrid","year":"2024","unstructured":"Madrid M, Lakshmipathy U, Zhang X et al (2024) Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC committee. Cytotherapy 26(11):1382\u20131399. https:\/\/doi.org\/10.1016\/j.jcyt.2024.05.022","journal-title":"Cytotherapy"}],"container-title":["Functional & Integrative Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-025-01756-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10142-025-01756-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-025-01756-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:11:42Z","timestamp":1769155902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10142-025-01756-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":217,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1756"],"URL":"https:\/\/doi.org\/10.1007\/s10142-025-01756-1","relation":{},"ISSN":["1438-793X","1438-7948"],"issn-type":[{"value":"1438-793X","type":"print"},{"value":"1438-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the preparation of this work, the author used Chatgpt in order to revise grammatical errors that appeared in the article. After using the tool\/service, the author reviewed and edited the content as necessary and takes full responsibility for the content of the publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"246"}}